A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Clinical trial NCT07602855 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07602855
- Sponsor
- GlaxoSmithKline
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-08
- Primary completion
- 2029-07-05
- Enrollment
- 184
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.